Israeli stroke therapy granted FDA breakthrough device status

Spread the love

“Stroke is a debilitating condition with limited recovery options, creating a huge unmet need.”

BrainQ's artificial intelligence stroke therapy. (photo credit: BRAINQ)

BrainQ’s artificial intelligence stroke therapy.

(photo credit: BRAINQ)

Israeli BrainQ’s artificial intelligence stroke therapy, that reduces disability following strokes, was given Breakthrough Device designation by the US Food and Drug Administration (FDA), the start up announced last week. The designation will allow BrainQ to work with the FDA to expedite the development and clearance process of BrainQ’s device.

Some 50 to 70% of those who suffer a stroke experience chronic disability in the aftermath of these events, according to BrainQ. BrainQ’s AI-powered, electromagnetic field therapy aims to reduce disability caused by stroke through a non-invasive therapy.

BrainQ’s therapy is designed to treat patients in the weeks and months following a stroke. Currently approved interventions for reducing disability following a stroke are only relevant in the first few hours following the stroke and only 5% of stroke victims reach the hospital in time to benefit from these, according to BrainQ, whose therapy aims to fill this gap.

READ ALSO:  1 millionth Israeli vaccinated falsely dubbed killer, KAN retracts

The FDA designation as a breakthrough device is given to treatments that can “provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions”.

BrainQ’s therapy is based on biological insights from brainwaves and uses machine learning algorithms that translate into frequency-tuned, low intensity electromagnetic fields. The therapy is delivered through a wearable device that is connected to the cloud. It is designed so that it is a portable treatment that can be used in the patient’s home.

“Stroke is a debilitating condition with limited recovery options, creating a huge unmet need,” said BrainQ CEO and Co-founder Yotam Drechsler.

“Covid-19 has only made things worse by limiting patients’ access to treatment facilities. FDA Breakthrough Designation is an important milestone in our mission to reduce disability for these patients and treat them in the comfort of their homes.”

 218 

RECOMMENDED READ:
Haredi Jews in Hungary threaten to sue Reform group for $33 million debt

Haredi Jews in Hungary demand $33m. from other communities for 'injustice' "We have been trying for years to settle this Read more

IDF completes underground wall as Israel readies for Hamas war

The IDF has completed the construction of the underground concrete wall between Israel and the Gaza Strip, as part of Read more

Why did Gila Gamliel blame the oil spill on Iran? – Background

Officials in the Mossad and the IDF have distanced themselves from Gamliel's claims that terrorism was the cause of the Read more

Leave a Reply